ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1795

Four Years Follow-up of Subclinical Atherosclerosis in Systemic Lupus Erythematosus Patients

Ju-Yang Jung1, Hyoun-Ah Kim1 and Chang-Hee Suh2, 1Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, 2Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, The Republic of

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Atherosclerosis and systemic lupus erythematosus (SLE), Disease Activity, Vitamin D

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) patients have increased risk of advanced atherosclerosis and cardiovascular disease. The mechanism of premature atherosclerosis in SLE is not completely understood, and systemic inflammation representing disease activity and traditional risk factors such as overweight and dyslipidemia have been regarded to contribute. Many SLE patients have low disease activity or sporadic occurrence of mild symptoms after a period of vigorous manifestations derived from autoimmune activation. It has not been evaluated whether SLE patients with mild activity have a risk of atherosclerosis progression, while it’s a common situation which many SLE patients are undergoing. Previously we evaluated subclinical atherosclerosis of SLE patients with mild disease activity by Doppler ultrasound 4 years ago. This time we checked them again and assessed which features affects their changes.

Methods: We assessed carotid artery intima-media thickness (cIMT) and carotid plaque by Doppler ultrasonography among sixty-one female SLE patients who were enrolled in the previous work 4 years ago, and analyzed the changes with clinical characteristics.  

Results: The SLE disease activity index of the participants was 4.2 ± 3.9, and 25(OH)D3 level was elevated than previous study (25.7 ± 6.9 vs 12.7 ± 8.6 ng/mL, p < 0.001), while other features were similar. The mean cIMT of SLE patients was 0.39 ± 0.09 mm and 11 patients had carotid plaques, which were not significantly different with previous study. Twenty one patients had the increased cIMT, while 35 patients had decreased cIMT. And new carotid plaque was developed in 7 SLE patients, while the carotid plaque of 10 SLE patients was resolved. The patients with increased cIMT had lower body mass index (BMI) (19.8 ± 1.8 vs 21.7 ± 3.1 kg/m2, p = 0.007), longer disease duration (102.0 ± 42.2 vs 74.8 ± 55.2 months, p = 0.006) and higher total steroid dose (18.5 ± 21.6 vs 10.5 ± 22.9 g, p < 0.001) compared with those not. The patients having new carotid plaque had lower high-density lipoprotein (HDL) cholesterol levels (41.6 ± 10.2 vs 55.6 ± 15.5 mg/dL, p = 0.024) and were taking higher doses of current steroid (8.9 ± 9.5 vs 3.6 ± 4.5mg, p = 0.008). On multiple regression analysis, BMI (0.62 [0.42 – 0.91], p = 0.01) and HDL cholesterol (0.94 [0.89 – 1.0], p = 0.02) were revealed to affect cIMT increment, and current steroid dose (1.14 [1.01 – 1.28], p = 0.04) were revealed to affect plaque development.  

Conclusion: BMI have been known to affect atherosclerosis and vitamin D deficiency has been known to associate with cardiovascular disease. In contrast of other studies, our data showed BMI contributed negatively cIMT increment. The result about BMI was regarded that very low BMI might have a harmful effect to atherosclerosis, considered that mean BMI was much lower (21.0 ± 2.8 kg/m2) than other studies.4 The follow up study for SLE patients with low disease activity showed low BMI and HDL cholesterol might be a risk factor for subclinical atherosclerosis and current steroid dose could be associated with plaque development.


Disclosure: J. Y. Jung, None; H. A. Kim, None; C. H. Suh, None.

To cite this abstract in AMA style:

Jung JY, Kim HA, Suh CH. Four Years Follow-up of Subclinical Atherosclerosis in Systemic Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/four-years-follow-up-of-subclinical-atherosclerosis-in-systemic-lupus-erythematosus-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/four-years-follow-up-of-subclinical-atherosclerosis-in-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology